Protara Therapeutics, Inc.
DE ˙ DB ˙ US74365U1079
€3,56 ↑0,14 (4,10%)
2026-06-05
HİSSE FİYATI
SecurityDE:1KPA / Protara Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership55,057 shares
Latest Disclosed Value $ 293,454
Barclays Plc reports 20.95% increase in ownership of 1KPA / Protara Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 55,057 shares of Protara Therapeutics, Inc. (DE:1KPA) valued at $244,453 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 45,520 shares of Protara Therapeutics, Inc.. This represents a change in shares of 20.95% during the quarter. The current value of the position is $195,783 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F PROTARA THERAPEUTICS COM 74365U107 55,057 9,537 20.95 293 47.98 0.0001
2026-03-31 2025-09-30 13F/A-3 PROTARA THERAPEUTICS COM 74365U107 45,520 -10,119 -18.19 198 17.86 0.0000
2025-11-12 2025-09-30 13F PROTARA THERAPEUTICS COM 74365U107 45,520 -10,119 198 0.0000
2026-02-27 2025-06-30 13F/A-2 PROTARA THERAPEUTICS COM 74365U107 55,639 -37,600 -40.33 169 -57.68 0.0000
2025-08-14 2025-06-30 13F/A-1 PROTARA THERAPEUTICS COM 74365U107 55,639 -37,600 0 0.0000
2025-08-13 2025-06-30 13F PROTARA THERAPEUTICS COM 74365U107 55,639 -37,600 0 0.0000
2026-03-17 2025-03-31 13F/A-1 PROTARA THERAPEUTICS COM 74365U107 93,239 0 0.00 397 -19.31 0.0001
2025-05-15 2025-03-31 13F PROTARA THERAPEUTICS COM 74365U107 93,239 0 0 0.0001
2026-03-19 2024-12-31 13F/A-1 PROTARA THERAPEUTICS COM 74365U107 93,239 93,239 492 0.0001
2025-02-13 2024-12-31 13F PROTARA THERAPEUTICS COM 74365U107 93,239 93,239 0 0.0001
2022-08-12 2022-06-30 13F PROTARA THERAPEUTICS COM 74365U107 0 -2,510 -100.00 0 -100.00
2022-05-16 2022-03-31 13F PROTARA THERAPEUTICS COM 74365U107 2,510 2,510 13 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.